$NBIO "Taking the time to navigate this opportunity with proper care and diligence is a step that demonstrates our commitment to the best interests of our investors, partners, shareholders, and potential future patients," remarked Sean Carrick, CEO of NBIO. "No one likes delays, but patience and care at this critical stage is necessary in maximizing patient outcomes and long-term shareholder value. We want to be careful not to make hasty decisions while exploring all options.

$NBIO .10 back up!

$NBIO huge news today! April 16, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, announces that it is embarking on a fresh manufacturing run to ensure Pritumumab ("PTB") supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial.

"Taking the time to navigate this opportunity with proper care and diligence is a step that demonstrates our commitment to the best interests of our investors, partners, shareholders, and potential future patients," remarked Sean Carrick, CEO of NBIO. "No one likes delays, but patience and care at this critical stage is necessary in maximizing patient outcomes and long-term shareholder value. We want to be careful not to make hasty decisions while exploring all options.

This announcement comes as the Company prepares for a Phase II trial that follows a very successful Phase I trial-where safety at five ascending dose cohorts was observed-involving 15 patients who received PTB for various types of brain tumors. The most common and most challenging to treat tumor type in the trial was Glioblastoma. 12 of 15 patients had this diagnosis.

There were no dose-related toxicities. Overall, the study found that single agent Pritumumab is safe up to a dose of 16.2 mg/kg every 7 days in brain tumor patients. One partial response showed a 98.0% and 40.8% reduction in 2 tumor lesions for 21 months on study.

$NBIO a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, announces that it is embarking on a fresh manufacturing run to ensure Pritumumab ("PTB") supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial. Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run https://finance.yahoo.com/news/nascent-prepares-pivotal-phase-ii-120000620.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

NBIO premarket news! Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run https://finance.yahoo.com/news/nascent-prepares-pivotal-phase-ii-120000620.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

$NBIO on my radar, loading up this week

$HPCO AI-Powered Innovation: Behind the Scenes of Hempacco's Rolling Paper Design Process https://thedailyguardian.com/ai-powered-innovation-behind-the-scenes-of-hempaccos-rolling-paper-design-process/

CYIO .017's a steal here

$CYIO adding .016's

$CYIO loading zone here

$CYIO heading for .02's!

@Heliolending Looking forward to an exciting new partnership coming soon including new crypto loan options and loan structures. #Bitcoin #crypto #lending

— Helio Lending - Wholly owned by @cyioscorp (CYIO) (@HelioLending) April 3, 2024

$CYIO @Heliolending Looking forward to an exciting new partnership coming soon including new crypto loan options and loan structures. #Bitcoin📷 #crypto #lending

@Heliolending Looking forward to an exciting new partnership coming soon including new crypto loan options and loan structures. #Bitcoin #crypto #lending

— Helio Lending - Wholly owned by @cyioscorp (CYIO) (@HelioLending) April 3, 2024

$CYIO CarbonCred: Reducing Carbon Footprints by Simplifying Carbon Offsetting for Businesses and Employees

$CYIO @CarbonCredio https://t.co/4r6WGFFARe

— CYIOS Corporation (@cyioscorp) April 3, 2024

$CYIO CarbonCred: Reducing Carbon Footprints by Simplifying Carbon Offsetting for Businesses and Employees https://marketdaily.com/carboncred-reducing-carbon-footprints-by-simplifying-carbon-offsetting-for-businesses-and-employees/

$CYIO nice and green here .0149 back up!

$CYIO per their latest tweet: "New partnership coming soon including new crypto loan options and loan structures."

CYIO +24.17% heading for a breakout!

@Heliolending Looking forward to an exciting new partnership coming soon including new crypto loan options and loan structures. #Bitcoin #crypto #lending

— Helio Lending - Wholly owned by @cyioscorp (CYIO) (@HelioLending) April 3, 2024

$CYIO on alert: "@Heliolending
Looking forward to an exciting new partnership coming soon including new crypto loan options and loan structures. #Bitcoin #crypto #lending"

@Heliolending Looking forward to an exciting new partnership coming soon including new crypto loan options and loan structures. #Bitcoin #crypto #lending

— Helio Lending - Wholly owned by @cyioscorp (CYIO) (@HelioLending) April 3, 2024

$CYIO new tweet! "@Heliolending
Looking forward to an exciting new partnership coming soon including new crypto loan options and loan structures. #Bitcoin #crypto #lending"

@Heliolending Looking forward to an exciting new partnership coming soon including new crypto loan options and loan structures. #Bitcoin #crypto #lending

— Helio Lending - Wholly owned by @cyioscorp (CYIO) (@HelioLending) April 3, 2024

Hearing news soon!

Watching for updates here!

$NBIO green here .17 ready to fall!

$NBIO Nascent CEO, Sean Carrick, commented: "We couldn't be more excited to work with HypoSpray's team and its leading delivery system technology. This collaboration has the potential to drive tangible breakthroughs in cancer treatment and patient care that enable home administration, eventually eliminating the need for bi-weekly multi-hour visits to the infusion center, materially improving quality of life for patients undergoing treatment."

$NBIO big news out today: March 19, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, and HypoSpray Pharma ("HypoSpray®"), a clinical and commercial stage drug delivery technology company, announced today a collaboration to develop an alternative delivery mechanism for patients who can benefit from Pritumumab ("PTB"), Nascent's lead monoclonal antibody cancer treatment asset, which is now in Phase II clinical research for the treatment of Brain Cancer.

Once successfully commercialized, the Company hopes to eliminate bi-weekly weekly infusions, allowing patients to administer Pritumumab and avoid inconvenient, tedious, and uncomfortable multi hour cancer center treatment visits.
https://finance.yahoo.com/news/nascent-collaborates-hypospray-pharma-proprietary-120000958.html

$NBIO Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System https://finance.yahoo.com/news/nascent-collaborates-hypospray-pharma-proprietary-120000958.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

$NBIO News Out! Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System https://finance.yahoo.com/news/nascent-collaborates-hypospray-pharma-proprietary-120000958.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

$STLNF (Newsfile Corp. - March 14, 2024) - CEO.CA Technologies Ltd. ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares comprehensive video coverage from the recent PDAC convention in Toronto, Canada.

Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc., is one of the most popular free financial websites and apps in Canada and for investors globally - with industry leading audience engagement and mobile functionality. Millions of people visit CEO.CA each year to connect with investors from around the world, share knowledge and view impactful stories about stocks, commodities, and emerging companies. https://finance.yahoo.com/news/ceo-ca-presents-pdac-recap-144500076.html

$STLNF on alert, big news this week: CEO.CA Presents PDAC Recap: Exclusive Interviews From Mining Leaders https://finance.yahoo.com/news/ceo-ca-presents-pdac-recap-144500076.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

$STLNF loading up, a steal under .10 here in power hour!

$STLNF huge updates here! https://finance.yahoo.com/quote/STLNF/press-releases

$STLNF Stallion Uranium Strengthens Technical Team https://finance.yahoo.com/news/stallion-uranium-strengthens-technical-team-113000275.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

$STLNF March 06, 2024 (GLOBE NEWSWIRE) -- Stallion Uranium Corp. (the "Company" or "Stallion") (TSX-V: STUD; OTCQB: STLNF; FSE: HM40) is pleased to announce that it has begun drilling on its high priority Appaloosa Target as part the Company’s maiden drill program on its 100% owned Coffer Project in the prolific Southwestern Athabasca Basin in Saskatchewan, Canada.

Highlights

The objective of the drill program is the discovery of uranium mineralization associated with conductive electromagnetic (EM) anomalies.

Drill holes are targeting multiple stacked geophysical anomalies including conductive EM anomalies, gravity low anomalies and magnetic low anomalies.

Approximately 3,300 meters are planned in 3 drill holes.

Stallion holds a 100% ownership of the project.

$STLNF news alert: Stallion Uranium Commences Drilling on Appaloosa Uranium Target https://finance.yahoo.com/news/stallion-uranium-commences-drilling-appaloosa-113000704.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

$STLNF Great discussion on #Uranium markets, future production/#exploration and why investors should be paying attention to the juniors! It was a pleasure to be part of the panel with
@CanAlaska
@UREnergyGlobal
@StandardUranium
@ceodotca
🙏

Great discussion on #Uranium markets, future production/#exploration and why investors should be paying attention to the juniors! It was a pleasure to be part of the panel with @CanAlaska @UREnergyGlobal @StandardUranium @ceodotca 🙏https://t.co/ozoNvkZ9cM$STUD $STLNF $STUD.V

— Stallion Uranium (@stallionuranium) March 13, 2024

$STLNF “Drilling marks a key milestone for Stallion as we move into more advanced exploration with potential to make a uranium discovery! We have been able to progress the Appaloosa target from a regional survey to an advanced drill target that hosts several known features associated with uranium mineralization,” stated Drew Zimmerman, CEO. “Our systematic approach over such a large land package gives our team high confidence in drill testing the Appaloosa target.”

$STLNF Stallion Uranium has the right to earn 100% interest in the Richmond Mountain project https://stallionuranium.com/projects/us-gold-critical-minerals/richmond-mountain/

$STLNF loading up this week: Stallion Uranium Announces Additional Uranium Property Staking, Further Expanding Largest Exploration Land Package in Southwestern Athabasca Basin https://finance.yahoo.com/news/stallion-uranium-announces-additional-uranium-113000019.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

$STLNF Stallion Uranium Commences Drilling on Appaloosa Uranium Target https://finance.yahoo.com/news/stallion-uranium-commences-drilling-appaloosa-113000704.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

$STLNF Stallion Uranium Engages Axiom Exploration for Aerial Gravity Survey over Gunter Lake Uranium Project https://finance.yahoo.com/news/stallion-uranium-engages-axiom-exploration-110000221.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

$STLNF .93's green here!